The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
In silico clinical trials: concepts and early adoptions
Abstract
Innovations in information and communication technology infuse all branches of science, including life sciences. Nevertheless, healthcare is historically slow in adopting technological innovation, compared with other industrial sectors. In recent years, new approaches in modelling and simulation have started to provide important insights in biomedicine, opening the way for their potential use in the reduction, refinement and partial substitution of both animal and human experimentation. In light of this evidence, the European Parliament and the United States Congress made similar recommendations to their respective regulators to allow wider use of modelling and simulation within the regulatory process. In the context of in silico medicine, the term ‘in silico clinical trials’ refers to the development of patient-specific models to form virtual cohorts for testing the safety and/or efficacy of new drugs and of new medical devices. Moreover, it could be envisaged that a virtual set of patients could complement a clinical trial (reducing the number of enrolled patients and improving statistical significance), and/or advise clinical decisions. This article will review the current state of in silico clinical trials and outline directions for a full-scale adoption of patient-specific modelling and simulation in the regulatory evaluation of biomedical products. In particular, we will focus on the development of vaccine therapies, which represents, in our opinion, an ideal target for this innovative approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systems biology: a brief overview
Kitano, H. (2002) · Science · doi:10.1126/science.1069492 · Cited by 4,265
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
A N EW A PPROACH TO D ECODING L IFE : Systems Biology
Ideker, T., Galitski, T., & Hood, L. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.343 · Cited by 1,664
Some suggestions for measuring predictive performance
Sheiner, L. B., & Beal, S. L. (1981) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01060893 · Cited by 1,617
Role of Molecular Dynamics and Related Methods in Drug Discovery
De Vivo, M., Masetti, M., Bottegoni, G., & Cavalli, A. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01684 · Cited by 1,297
Lindbom, L., Pihlgren, P., & Jonsson, N. (2005) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2005.04.005 · Cited by 1,135
Peters, B., & Sette, A. (2005) · BMC Bioinformatics · doi:10.1186/1471-2105-6-132 · Cited by 512
Reverse vaccinology, a genome-based approach to vaccine development
Rappuoli, R. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00554-5 · Cited by 497
Computational fluid dynamics modelling in cardiovascular medicine
Morris, P. D., Narracott, A., von Tengg-Kobligk, H., Silva Soto, D. A., Hsiao, S., Lungu, A., Evans, P., Bressloff, N. W., Lawford, P. V., Hose, D. R., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308044 · Cited by 495
De Vito, C., Angeloni, C., De Feo, E., Marzuillo, C., Lattanzi, A., Ricciardi, W., Villari, P., & Boccia, S. (2014) · BioMed Research International · doi:10.1155/2014/304602 · Cited by 451
Research works printed but not linked: 15
- Silverman, 1961, Application of analogue computer to measurement of intestinal absorption rates with tracers, J Appl Physiol, 16, 911, 10.1152/jappl.1961.16.5.911 · doi:10.1152/jappl.1961.16.5.911
- Nichol, 1977, Pharmacokinetics: selectivity of action related to physicochemical properties and kinetic patterns of anticancer drugs, Cancer, 40, 519, 10.1002/1097-0142(197707)40:1+<519::AID-CNCR2820400718>3.0.CO;2-4 · doi:10.1002/1097-0142(197707)40:1+<519::aid-cncr2820400718>3.0.co;2-4
- Cogan, 1984, Regulation of proximal bicarbonate reabsorption, Am J Physiol, 247, F387
- Byczkowski, 1994, Computer simulation of the lactational transfer of tetrachloroethylene in rats using a physiologically based model, Toxicol Appl Pharmacol, 125, 228, 10.1006/taap.1994.1068 · doi:10.1006/taap.1994.1068
- Bassingthwaighte, 1997, Design and strategy for the Cardionome Project, Adv Exp Med Biol, 430, 325, 10.1007/978-1-4615-5959-7_28 · doi:10.1007/978-1-4615-5959-7_28
- Popel, 1998, The microcirculation physiome project, Ann Biomed Eng, 26, 911, 10.1114/1.112 · doi:10.1114/1.112
- Calonaci, 2012, Optimal vaccination schedule search using genetic algorithm over MPI technology, BMC Med Inform Decis Mak, 12, 129., 10.1186/1472-6947-12-129 · doi:10.1186/1472-6947-12-129
- Peleg, 2004, Using Petri Net tools to study properties and dynamics of biological systems, J Am Med Inform Assoc, 12, 181, 10.1197/jamia.M1637 · doi:10.1197/jamia.m1637
- Cordero, 2013, Multi-level model for the investigation of oncoantigen-driven vaccination effect, BMC Bioinformatics, 14, S11., 10.1186/1471-2105-14-S6-S11 · doi:10.1186/1471-2105-14-s6-s11
- Pennisi, 2016, A methodological approach for using high-level Petri Nets to model the immune system response, BMC Bioinformatics, 17, 498, 10.1186/s12859-016-1361-6 · doi:10.1186/s12859-016-1361-6
- Lemon, 2016, The use of mathematical modelling for improving the tissue engineering of organs and stem cell therapy, Curr Stem Cell Res Ther, 11, 666, 10.2174/1574888X10666151001115942 · doi:10.2174/1574888x10666151001115942
- Ravvaz, 2017, Personalized anticoagulation: optimizing Warfarin management using genetics and simulated clinical trials, Circ Cardiovasc Genet, 10, e001804, 10.1161/CIRCGENETICS.117.001804 · doi:10.1161/circgenetics.117.001804
- Pappalardo, 2015, Computational modelling approaches to vaccinology, Pharmacol Res, 92, 40, 10.1016/j.phrs.2014.08.006 · doi:10.1016/j.phrs.2014.08.006
- Viceconti, 2009, Pre-clinical validation of joint prostheses: a systematic approach, J Mech Behav Biomed Mater, 2, 120, 10.1016/j.jmbbm.2008.02.005 · doi:10.1016/j.jmbbm.2008.02.005
- Alemani, 2012, Combining cellular automata and Lattice Boltzmann method to model multiscale avascular tumor growth coupled with nutrient diffusion and immune competition, J Immunol Methods, 376, 55, 10.1016/j.jim.2011.11.009 · doi:10.1016/j.jim.2011.11.009
Cited by
The ‘Digital Twin’ to enable the vision of precision cardiology
Corral-Acero, J., Margara, F., Marciniak, M., Rodero, C., Loncaric, F., Feng, Y., Gilbert, A., Fernandes, J. F., Bukhari, H. A., Wajdan, A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa159 · Cited by 932
Lekadir, K., Frangi, A. F., Porras, A. R., Glocker, B., Cintas, C., Langlotz, C. P., Weicken, E., Asselbergs, F. W., Prior, F., Collins, G. S., et al. (2025) · BMJ · doi:10.1136/bmj-2024-081554 · Cited by 957
Viceconti, M., Pappalardo, F., Rodriguez, B., Horner, M., Bischoff, J., & Musuamba Tshinanu, F. (2021) · Methods · doi:10.1016/j.ymeth.2020.01.011 · Cited by 361
“Thus, human in silico clinical trials are now emerging as an important paradigm in the development of medical therapies [6].”
BackgroundSelf-citationFDA Perspective on the Regulation of Artificial Intelligence in Health Care and Biomedicine
Warraich, H. J., Tazbaz, T., & Califf, R. M. (2025) · JAMA · doi:10.1001/jama.2024.21451 · Cited by 332
Synthetic data in health care: A narrative review
Gonzales, A., Guruswamy, G., & Smith, S. R. (2023) · PLOS Digital Health · doi:10.1371/journal.pdig.0000082 · Cited by 308
Metadata
- Authors
- Pappalardo, F., Russo, G., Tshinanu, F. M., & Viceconti, M.
- Venue
- Briefings in Bioinformatics
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-06-02
- Volume
- 20
- Issue
- 5
- Pages
- 1699-1708
- ISSN
- 1467-5463 (ISSN-L)
- 1477-4054
- OpenAlex
- W2806810105
- Cited by
- 279
- References
- 59
- FWCI
- 10.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In silico clinical trials: concepts and early adoptions. https://app.cochat.ai/papers/10.1093/bib/bby043
- The paper
- Pappalardo, F., Russo, G., Tshinanu, F. M., & Viceconti, M. (2019). In silico clinical trials: concepts and early adoptions. Briefings in Bioinformatics. https://doi.org/10.1093/bib/bby043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.